Rocket Pharmaceuticals, Inc. (RCKT) Cash Flow Statement

The negative OCF-to-NI ratio in 2026Q2 is the sharpest conversion breakdown in the ten-quarter series and directly corroborates the income statement finding of an anomalous non-operating gain; because operating cash flow did not turn positive in the same period, the $123.2M appears to reflect an unrealized fair-value remeasurement or non-cash accounting recognition rather than a realized, cash-settled licensing event. Investors should treat any trailing valuation multiple anchored to that quarter's net income as unreliable. Conversely, in the nine loss-making quarters the OCF-to-NI ratios cluster tightly between 0.71 and 1.00, which suggests that RCKT's reported operating losses translate into cash burn with relatively low accrual distortion — a comparatively clean conversion profile absent one-time events.

The narrowing trajectory through 2025 aligns with the SG&A compression documented in the prior income statement analysis, which implies the cash improvement is a function of overhead discipline rather than any commercial or clinical monetization. The re-widening of burn in 2026Q1 to -$45.5M interrupts that trend and raises a question of whether the leaner cost base is proving durable or whether R&D spend is re-accelerating into late-stage programs. Cumulative FCF consumption of approximately -$485M over the ten quarters establishes a scale of capital need that appears to require continued external financing absent a revenue inflection.

The de minimis capex line suggests that RCKT does not hold significant owned manufacturing capacity and is instead reliant on third-party CDMOs, which shifts fixed-asset risk off the balance sheet but may carry higher per-unit economics and reduced supply chain control as programs scale. Analysts should also note that quarterly D&A of $2.1M to $3.2M materially exceeds capex in every period, implying the company is not reinvesting to replace its existing asset base — a pattern consistent with either an outsourcing strategy or an intentional wind-down of owned infrastructure. The maintenance-versus-growth capex distinction is effectively moot here, as the entirety of the burn is absorbed in R&D and SG&A.

Stripping out 2026Q2, the underlying nine-quarter picture actually shows cumulative operating cash flow running modestly better than cumulative net income by roughly $44M, which is directionally consistent with the substantial non-cash addbacks — principally cumulative SBC of approximately $93M and cumulative D&A of approximately $25M — partially offsetting working capital swings. The critical analytical implication is that RCKT's reported loss trend is a reasonable proxy for its true cash consumption in normal periods, but that any single quarter containing a large non-cash gain will severely distort the cumulative divergence and should be normalized before being incorporated into a multi-year earnings power estimate.